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In Reply Dr Sugiyama suggested some possible mechanisms
for our results and directions for further research. We agree
that it is worth investigating whether dabigatran could
reduce the risk of falls in future studies. We were unable to
look in detail at hip and vertebral fractures separately
because of the small number of events; even the composite
outcome was rare (<1.0 per 100 person-years). Additional
studies that examine the risk of falls, as well as fall-related
and fall-unrelated fractures, are therefore warranted to
evaluate the possible roles of dabigatran and warfarin in
association with fracture risk, especially among patients
receiving short-term treatment (<1 year).
Although the lower risk of fractures with short-term
treatment may be less likely to result from changes in bone
fragility, we think that this might not necessarily preclude
any biological effects of dabigatran or warfarin on bone
because we also observed a lower risk for long-term use
(≥1 year). Further, an animal study reported that dabigatran
use was associated with higher bone volume, reduced tra-
becular separation, and lower bone turnover rate compared
with warfarin use.1 It would be useful to determine the
effect on bone, together with the risk of falls and individual
types of fractures, with the use of dabigatran vs warfarin in
future studies.
Althoughsomestudiessuggest thatwarfarinmaynotcause
fragility fractures,2previousevidencewasmainlyderived from
studies using untreated or unmatched patients as the com-
paratorwithwarfarin, and so thepotential for confoundingby
indication cannot be ignored.2However, at the time the stud-
ieswereconducted,nocomparatorwithsimilar indicationsex-
isted because warfarin was the only treatment choice avail-
able.With theavailabilityofNOACs, therewill beopportunities
for reliable comparisons with warfarin with respect to frac-
ture risk. Further comparisons between different NOACs, as
suggested by Sugiyama,will provide further insights into any
mechanistic differences betweenNOACswith respect to frac-
ture risk, aswell as informthechoiceoforal anticoagulantpre-
scribed in clinical practice.
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